Editas Medicine Inc

NASDAQ:EDIT   3:59:58 PM EDT
41.87
-0.03 (-0.07%)
Products, Regulatory

Editas Medicine Announces Enrollment Of The First Pediatric Cohort In The Brilliance Clinical Trial Of Edit-101 For The Treatment Of Lca10 Following Idmc Endorsement

Published: 06/23/2021 11:17 GMT
Editas Medicine Inc (EDIT) - Editas Medicine Announces Enrollment of the First Pediatric Cohort in the Brilliance Clinical Trial of Edit-101 for the Treatment of Lca10 Following Idmc Endorsement.
Editas Medicine Inc - Plans to Report Initial Edit-101 Clinical Data in September.
Editas Medicine - for Pediatric Mid-dose Cohort & Adult High-dose Cohort, First Dosing Expected This Summer & Completion is Expected in H1 of 2022.